Industry's Rebate Arms Race: Securing Market Access At A Cost
This article was originally published in Scrip
Executive Summary
Rebates have become industry's go-to for securing market access for drugs in competitive therapeutic areas in the US. But as payers push back, competitive rebating is intensifying and eating into the bottom line.